Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cell therapy SYNCAR-100 tested in Tough-to-Treat leukemia

NCT ID NCT07429461

Recruiting now Disease control Sponsor: Zhejiang University Source: ClinicalTrials.gov ↗

First seen Feb 28, 2026 · Last updated May 11, 2026 · Updated 12 times

Summary

This early study tests a new treatment called SYNCAR-100 in 16 adults with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back or not responded to standard therapy. The main goal is to check safety and side effects, while also seeing if the treatment can shrink the cancer. Participants receive the drug once a week for four weeks and are followed for one year, with long-term monitoring up to 15 years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The first affiliated hospital of medical college of zhejiang university

    RECRUITING

    Hangzhou, Zhejiang, 310003, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA